Bayer (FRA:BAYN) has been given a €110.00 ($127.91) target price by analysts at UBS Group in a note issued to investors on Thursday, www.boersen-zeitung.de reports. The brokerage presently has a “buy” rating on the healthcare company’s stock. UBS Group’s price objective indicates a potential upside of 73.42% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on shares of Bayer and gave the company a “buy” rating in a research note on Monday, August 13th. Commerzbank set a €111.00 ($129.07) target price on shares of Bayer and gave the company a “buy” rating in a research note on Monday, August 13th. Barclays set a €110.00 ($127.91) target price on shares of Bayer and gave the company a “buy” rating in a research note on Monday, August 13th. Goldman Sachs Group set a €116.00 ($134.88) target price on shares of Bayer and gave the company a “buy” rating in a research note on Monday, August 13th. Finally, Cfra set a €100.00 ($116.28) target price on shares of Bayer and gave the company a “buy” rating in a research note on Tuesday, August 14th. Six investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of €90.80 ($105.58).

Shares of BAYN stock opened at €63.43 ($73.76) on Thursday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: Can individual investors take part in an IPO?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.